Government Briefs

The rancor of the White House cost David T. Kingsbury, National Science Foundation assistant director for behavioral and biological sciences, a trip to Paris last month. It seems that officials of the Administrations’s Office of Science and Technology Policy are trying to punish him because of allegations that he advised a California biotechnology firm while a government official (see The Scientist, November 2, 1987, p. 3). So they forced Kingsbury’s superiors at NSF to withdraw hi

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

The rancor of the White House cost David T. Kingsbury, National Science Foundation assistant director for behavioral and biological sciences, a trip to Paris last month. It seems that officials of the Administrations’s Office of Science and Technology Policy are trying to punish him because of allegations that he advised a California biotechnology firm while a government official (see The Scientist, November 2, 1987, p. 3). So they forced Kingsbury’s superiors at NSF to withdraw his name from the guest list of a biotechnology meeting sponsored by the multinational Organization of Economic and Cooperative Development. This gailed the NSF officials because their investigation had cleared Kingsbury of alleged conflict of interest last summer. But he’s not yet free of the Justice Department, which is moving very slowly on its own investigation of charges first made last fall.

Financial tremors are running through the controversial NSF-funded Earthquake Research Center that the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies